The Surge In Thyroid Cancer Prevalence And Its Implications On The Diagnostic Market: Critical Driver Shaping the Global Thyroid Cancer Diagnostics Market in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Thyroid Cancer Diagnostics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for diagnosing thyroid cancer has experienced considerable expansion lately, projected to increase its value from $2.99 billion in 2024 to $3.15 billion by 2025, reflecting a compound annual growth rate of 5.5%; this upward trend during the past period is linked to the greater incidence of thyroid malignancies, demographic shifts towards older age groups, heightened public consciousness leading to earlier identification, support from governmental programs and financial backing, and enhancements in healthcare facilities.

Thyroid Cancer Diagnostics Market Size Forecast: What's the Projected Valuation by 2029?
The diagnostic sector for thyroid cancer anticipates substantial expansion in the forthcoming years, projecting a market valuation of $3.99 billion by 2029, with a projected compound annual growth rate (CAGR) reaching 6.1%. This upward trajectory throughout the forecast term is primarily fueled by the rising need for companion diagnostics, a growing inclination among patients toward customized medical interventions, advancements in economies alongside increased expenditure on healthcare services, enhanced educational initiatives and professional development for physicians, and the successful achievement of necessary regulatory clearances and approvals. Key transformative movements expected to influence this market during the forecast period encompass the adoption of liquid biopsies, the international expansion of diagnostic tools, continuous technological innovation, intensified focus on research and development activities, the integration of artificial intelligence methodologies, and the formation of strategic alliances and cooperative agreements.

View the full report here:
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report

What Are the Drivers Transforming the Thyroid Cancer Diagnostics Market?
The growing incidence of thyroid cancer is expected to fuel the expansion of the thyroid cancer diagnostic market in the coming years. Thyroid cancer affects the thyroid gland, located at the base of the throat, which produces hormones responsible for regulating body temperature, heart rate, blood pressure, and weight. Diagnostic tests for thyroid cancer play a crucial role in early detection, leading to better treatment outcomes. Hence, the rising prevalence of thyroid cancer is increasing the demand for diagnostic solutions. For example, in September 2023, according to a report by the American Cancer Society, a US-based non-profit organization, approximately 43,720 new thyroid cancer cases were expected in 2023-12,540 in men and 31,180 in women-with an estimated 2,120 deaths (970 men and 1,150 women). Therefore, the growing prevalence of thyroid cancer is driving the growth of the thyroid cancer diagnostic market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12030&type=smp

What Long-Term Trends Will Define the Future of the Thyroid Cancer Diagnostics Market?
Key players within the thyroid cancer diagnostic sector are actively innovating by introducing sophisticated methods, such as RNA sequencing assays, aimed at boosting the precision with which cancerous fusions are identified across various carcinomas, thyroid cancer included. This RNA-Seq methodology represents a powerful, high-volume approach for assessing both the abundance and exact sequence of RNA present in a specimen, thereby yielding significant data regarding gene activity levels and the complete cellular transcriptome. Illustratively, in the month spanning March 2024, Foundation Medicine, Inc., a biotechnology firm situated in the United States, unveiled the North American introduction of FoundationOne RNA; this specific test utilizes tissue samples and RNA sequencing technology to pinpoint alterations in gene fusions across a panel of 318 genes. This capability allows for fusion detection reporting applicable to all solid tumors, proving especially beneficial for uncovering fusions in malignancies such as NSCLC, various sarcomas, pancreatic carcinoma, thyroid neoplasia, cholangiocarcinoma, and bladder malignancies.

Which Segments in the Thyroid Cancer Diagnostics Market Offer the Most Profit Potential?
The thyroid cancer diagnosticsmarket covered in this report is segmented -

1) By Technique Type: Imaging Test; Blood Test; Biopsy; Other Test Type
2) By Disease Type: Papillary Carcinoma; Follicular Carcinoma; Other Diseases
3) By End-User: Hospital Laboratories; Cancer Diagnostic Centers; Research Institutes; Other End-Users

Subsegments:
1) By Imaging Test: Ultrasound Imaging; Computed Tomography (CT) Scans; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET) Scans; Radioactive Iodine Scans
2) By Blood Test: Thyroid Function Tests; Tumor Marker Tests; Genetic Testing For Thyroid Cancer
3) By Biopsy: Fine Needle Aspiration (FNA) Biopsy; Core Needle Biopsy; Surgical Biopsy
4) By Other Test Type: Molecular Diagnostics; Immunohistochemistry Tests; Histopathological Analysis

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12030&type=smp

Which Firms Dominate the Thyroid Cancer Diagnostics Market by Market Share and Revenue in 2025?
Major companies operating in the thyroid cancer diagnostics market include Pfizer Inc., General Electric, F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Toshiba Corporation, Merck KGaA, Siemens Healthcare GmbH, FUJIFILM Holdings Corporation, Koninklijke Philips N.V., AstraZeneca plc, Agilent Technologies Inc., Hologic Inc., Genzyme Corporation, Illumina Inc., BioMérieux SA, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., Qiagen N.V., Cepheid, Veracyte Inc., DiaSorin S.p.A., Myriad Genetics Inc.

Which Regions Offer the Highest Growth Potential in the Thyroid Cancer Diagnostics Market?
North America was the largest region in the thyroid cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12030

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.